ConductScience.org, home

Paper17616675

Podocalyxin increases the aggressive phenotype of breast and prostate cancer cells in vitro through its interaction with ezrin.

Sizemore S and 4 others. Cancer Res, 2007. Cited by 116 papers, by iCite.

Cite this record

ConductScience Library. Podocalyxin increases the aggressive phenotype of breast and prostate cancer cells in vitro through its interaction with ezrin. Papers, record 17616675. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17616675

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Podocalyxin increases the aggressive phenotype of breast and prostate cancer cells in vitro through its interaction with ezrin.
PubMed
Journal
Cancer Res
PubMed
Year
2007
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural
PubMed
Citations, by iCite
116
iCite
Relative citation ratio, by iCite
2.32
iCite
Revised in PubMed
2026-08-08
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Sizemore SSteven
2Cicek MMuzaffer
3Sizemore NNywana
4Ng KPKwok Peng
5Casey GGraham

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Breast NeoplasmsMajor topic
Cytoskeletal ProteinsMajor topic
Gene Expression Regulation, NeoplasticMajor topic
Prostatic NeoplasmsMajor topic
SialoglycoproteinsMajor topic
Cell Line, Tumor
Female
Humans
MAP Kinase Signaling System
Male
Matrix Metalloproteinase 1
Matrix Metalloproteinase 9
Neoplasm Invasiveness
Phenotype
Phosphatidylinositol 3-Kinases
Ezrin

Source PubMed

Download CSV of topics

Grants5

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
CA88164NCI NIH HHSUnited StatesR01CA088164PubMed and NIHNIH RePORTER
R01 CA087728NCI NIH HHSUnited StatesR01CA087728PubMedNIH RePORTER
CA98683NCI NIH HHSUnited StatesR01CA098683PubMed and NIHNIH RePORTER
P50 CA089019NCI NIH HHSUnited StatesP50CA089019PubMedNIH RePORTER
R01 CA100748NCI NIH HHSUnited StatesR01CA100748PubMedNIH RePORTER

Download CSV of grants

Cited by84

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 116 citations.

PMIDTitleJournalYearIn PapersSource
42936515Claudin 1 promotes blood-borne metastasis by modulating the Src/Ezrin signaling pathway in high-CLDN1 triple-negative breast cancer model.Mol Cell Oncol2026https://conductscience.org/library/papers/42936515PubMed
42699358Monocyte-Macrophage Lineages in Cancer: Biology, Plasticity, and Therapeutic Targeting.Cancer Biome Target Ther2026https://conductscience.org/library/papers/42699358PubMed
41854948PODXL2 Promotes Cholangiocarcinoma Progression via Interactions with Ezrin and Activation of the MAPK/ERK1/2 and PI3K/AKT Signaling Pathways.Dig Dis Sci2026https://conductscience.org/library/papers/41854948PubMed
41462970Podocalyxin, Isthmin-1, and Pentraxin-3 Immunoreactivities as Emerging Immunohistochemical Markers of Fibrosis in Chronic Hepatitis B.Biomedicines2025https://conductscience.org/library/papers/41462970PubMed
41059339Posttranslational microtubule modification alters podocalyxin-trafficking in epithelial cells.Front Cell Dev Biol2025https://conductscience.org/library/papers/41059339PubMed
40953793Hyperactive PDGFRβ signaling induces cataractogenesis via TGFβ and STAT5-IGF1.Dev Biol2025https://conductscience.org/library/papers/40953793PubMed
40071026Rhoifolin: A promising flavonoid with potent cytotoxic and anticancer properties: molecular mechanisms and therapeutic potential.EXCLI J2025https://conductscience.org/library/papers/40071026PubMed
39294825Tumor endothelium-derived PODXL correlates with immunosuppressive microenvironment and poor prognosis in cervical cancer patients receiving radiotherapy or chemoradiotherapy.Biomark Res2024https://conductscience.org/library/papers/39294825PubMed
39272901The RAL Small G Proteins Are Clinically Relevant Targets in Triple Negative Breast Cancer.Cancers (Basel)2024https://conductscience.org/library/papers/39272901PubMed
39262484Has_circ_0002360 promotes the progression of lung adenocarcinoma by activating miR-762 and regulating PODXL expression.Transl Cancer Res2024https://conductscience.org/library/papers/39262484PubMed
39186674CRISPR Screening of Transcribed Super-Enhancers Identifies Drivers of Triple-Negative Breast Cancer Progression.Cancer Res2024https://conductscience.org/library/papers/39186674PubMed
39055653Role of actin-binding proteins in prostate cancer.Front Cell Dev Biol2024https://conductscience.org/library/papers/39055653PubMed
38376199Keratan sulfate, an electrosensory neurosentient bioresponsive cell instructive glycosaminoglycan.Glycobiology2024https://conductscience.org/library/papers/38376199PubMed
38203331A Cancer-Specific Monoclonal Antibody against Podocalyxin Exerted Antitumor Activities in Pancreatic Cancer Xenografts.Int J Mol Sci2023https://conductscience.org/library/papers/38203331PubMed
37304805Ezrin Immunoexpression in Prostate Adenocarcinomas.Curr Health Sci J2022https://conductscience.org/library/papers/37304805PubMed
36735782Spatial regulation of the glycocalyx component podocalyxin is a switch for prometastatic function.Sci Adv2023https://conductscience.org/library/papers/36735782PubMed
35992085Multifaceted role of RNA editing in promoting loss-of-function of PODXL in cancer.iScience2022https://conductscience.org/library/papers/35992085PubMed
35930100MiR-199a-5p-containing macrophage-derived extracellular vesicles inhibit SMARCA4 and alleviate atherosclerosis by reducing endothelial cell pyroptosis.Cell Biol Toxicol2023https://conductscience.org/library/papers/35930100PubMed
35711462Podocalyxin Expressed in Antigen Presenting Cells Promotes Interaction With T Cells and Alters Centrosome Translocation to the Contact Site.Front Immunol2022https://conductscience.org/library/papers/35711462PubMed
35491830The Lectin LecB Induces Patches with Basolateral Characteristics at the Apical Membrane to Promote Pseudomonas aeruginosa Host Cell Invasion.mBio2022https://conductscience.org/library/papers/35491830PubMed

See all 84 cited byDownload CSV of cited by

Genes5

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
EZR7430Swiss-Prot's referenceshttps://conductscience.org/library/genes/7430NCBI Gene
PODXL5420Swiss-Prot's referenceshttps://conductscience.org/library/genes/5420NCBI Gene
MMP14312PubTator's text mininghttps://conductscience.org/library/genes/4312NCBI Gene
MMP94318PubTator's text mininghttps://conductscience.org/library/genes/4318NCBI Gene
PIK3R15295PubTator's text mininghttps://conductscience.org/library/genes/5295NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/17616675

GET https://conductscience.org/api/papers/v1/17616675/cited_by?page=2